Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 186

1.

HIV-HCV Coinfection.

Sethi A, Sterling RK.

Gastroenterol Hepatol (N Y). 2006 May;2(5):357-365.

2.

Phase 3 trial of first generation protease inhibitor therapy for hepatitis C virus/human immunodeficiency virus coinfection.

Sherman KE, Kang M, Sterling R, Umbleja T, Marks K, Kiser JJ, Alston-Smith B, Greaves W, Butt AA, The Actg Birth Study Team.

World J Hepatol. 2017 Feb 8;9(4):217-223. doi: 10.4254/wjh.v9.i4.217.

3.

Grazoprevir and Elbasvir in Patients with Genotype 1 Hepatitis C Virus Infection: A Comprehensive Efficacy and Safety Analysis.

Yao Y, Yue M, Wang J, Chen H, Liu M, Zang F, Li J, Zhang Y, Huang P, Yu R.

Can J Gastroenterol Hepatol. 2017;2017:8186275. doi: 10.1155/2017/8186275.

4.
5.

Identification of the transcripts associated with spontaneous HCV clearance in individuals co-infected with HIV and HCV.

Chen Y, Shen C, Guha D, Ding M, Kulich S, Ashimkhanova A, Rinaldo C, Seaberg E, Margolick JB, Stosor V, Martínez-Maza O, Gupta P.

BMC Infect Dis. 2016 Nov 22;16(1):693.

6.

Seroprevalence of hepatitis C virus among people living with HIV/AIDS in Latin America and the Caribbean: a systematic review.

Tengan FM, Ibrahim KY, Dantas BP, Manchiero C, Magri MC, Bernardo WM.

BMC Infect Dis. 2016 Nov 9;16(1):663.

7.

Building a Community - Academic Partnership to Enhance Hepatitis C Virus Screening.

Irvin R, McAdams-Mahmoud A, Hickman D, Wilson J, Fenwick W, Chen I, Irvin N, Falade-Nwulia O, Sulkowski M, Chaisson R, Thomas DL, Mehta SH.

J Community Med Health Educ. 2016 Jun;6(3). pii: 431. Epub 2016 May 30.

8.

Statin drugs decrease progression to cirrhosis in HIV/HCV co-infected individuals.

Oliver NT, Hartman CM, Kramer JR, Chiao EY.

AIDS. 2016 Aug 3. [Epub ahead of print]

PMID:
27490640
9.

Hepatitis C treatment initiation in HIV-HCV coinfected patients.

Cotte L, Pugliese P, Valantin MA, Cuzin L, Billaud E, Duvivier C, Naqvi A, Cheret A, Rey D, Pradat P, Poizot-Martin I; Dat’AIDS study Group..

BMC Infect Dis. 2016 Jul 22;16:345. doi: 10.1186/s12879-016-1681-1.

10.

Liver fibrosis progression and clinical outcomes are intertwined: role of CD4+ T-cell count and NRTI exposure from a large cohort of HIV/HCV-coinfected patients with detectable HCV-RNA: A MASTER cohort study.

Focà E, Fabbiani M, Prosperi M, Quiros Roldan E, Castelli F, Maggiolo F, Di Filippo E, Di Giambenedetto S, Gagliardini R, Saracino A, Di Pietro M, Gori A, Sighinolfi L, Pan A, Postorino MC, Torti C; Italian MASTER Cohort..

Medicine (Baltimore). 2016 Jul;95(29):e4091. doi: 10.1097/MD.0000000000004091.

11.

Management of Hepatitis C/HIV Coinfection in the Era of Highly Effective Hepatitis C Virus Direct-Acting Antiviral Therapy.

Wyles DL, Sulkowski MS, Dieterich D.

Clin Infect Dis. 2016 Jul 15;63 Suppl 1:S3-S11. doi: 10.1093/cid/ciw219.

PMID:
27363438
13.

KASL clinical practice guidelines: management of hepatitis C.

Korean Association for the Study of the Liver..

Clin Mol Hepatol. 2016 Mar;22(1):76-139. doi: 10.3350/cmh.2016.22.1.76. Review. No abstract available.

14.

Hyperbilirubinaemia in HIV-HCV co-infected patients on antiretroviral therapy: drug effect or liver disease severity?

Kaspar MB, Sterling RK.

BMJ Open Gastroenterol. 2016 Mar 2;3(1):e000072. doi: 10.1136/bmjgast-2015-000072.

15.

Clinical Liver Disease Progression Among Hepatitis C-Infected Drug Users With CD4 Cell Count Less Than 200 Cells/mm(3) Is More Pronounced Among Women Than Men.

Baranoski AS, Cotton D, Heeren T, Nunes D, Kubiak RW, Horsburgh CR Jr.

Open Forum Infect Dis. 2015 Dec 31;3(1):ofv214. doi: 10.1093/ofid/ofv214.

16.

Real-World Sustained Virologic Response Rates of Sofosbuvir-Containing Regimens in Patients Coinfected With Hepatitis C and HIV.

Del Bello D, Cha A, Sorbera M, Bichoupan K, Levine C, Doyle E, Harty A, Patel N, Ng M, Gardenier D, Odin J, Schiano TD, Fierer DS, Berkowitz L, Perumalswami PV, Dieterich DT, Branch AD.

Clin Infect Dis. 2016 Jun 15;62(12):1497-504. doi: 10.1093/cid/ciw119.

PMID:
26936665
17.
18.

CD4+ T-cell recovery with suppressive ART-induced rapid sequence evolution in hepatitis C virus envelope but not NS3.

Liu L, Nardo D, Li E, Wang GP.

AIDS. 2016 Mar 13;30(5):691-700. doi: 10.1097/QAD.0000000000000997.

19.

Cholesterol Levels in HIV- and/or HCV-Infected Drug Users Living in Argentina.

Kohli R, Winston D, Sheehan H, Muzzio E, Benetucci J, Weissenbacher M, Wanke C, Knox T, Tang A.

J Int Assoc Provid AIDS Care. 2016 Sep;15(5):400-5. doi: 10.1177/2325957415614650.

20.

Reduced healthcare utilization following successful hepatitis C virus treatment in HIV-co-infected patients with mild liver disease.

Padam P, Clark S, Irving W, Gellissen R, Thomson E, Main J, Cooke GS.

J Viral Hepat. 2016 Feb;23(2):123-9. doi: 10.1111/jvh.12484.

Supplemental Content

Support Center